These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 36371234)

  • 1. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
    van Schaik M; Arends EJ; Soonawala D; van Ommen E; de Leeuw K; Limper M; van Paassen P; Huizinga TWJ; Toes REM; van Kooten C; Rotmans JI; Rabelink TJ; Teng YKO
    Trials; 2022 Nov; 23(1):939. PubMed ID: 36371234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
    Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
    Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
    Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
    BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial.
    Shipa M; Embleton-Thirsk A; Parvaz M; Santos LR; Muller P; Chowdhury K; Isenberg DA; Doré CJ; Gordon C; Ehrenstein MR;
    Ann Intern Med; 2021 Dec; 174(12):1647-1657. PubMed ID: 34698499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.
    Kraaij T; Arends EJ; van Dam LS; Kamerling SWA; van Daele PLA; Bredewold OW; Ray A; Bakker JA; Scherer HU; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
    Nephrol Dial Transplant; 2021 Jul; 36(8):1474-1483. PubMed ID: 32591783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
    Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
    J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
    Steiger S; Ehreiser L; Anders J; Anders HJ
    Front Immunol; 2022; 13():999704. PubMed ID: 36211360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belimumab for the treatment of pediatric patients with lupus nephritis.
    Stohl W; Kwok A
    Expert Opin Biol Ther; 2023 Mar; 23(3):243-251. PubMed ID: 36750049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current role of rituximab in systemic lupus erythematosus.
    Mok CC
    Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
    Staveri C; Karokis D; Liossis SC
    Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.
    Hui-Yuen JS; Nguyen SC; Askanase AD
    Lupus; 2016 Sep; 25(10):1086-96. PubMed ID: 27497253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy.
    Liu D; Zhou Q; Wang D; Qu Y; Guo Q; Wen J; Yu Q; Ai J
    Lupus; 2022 Oct; 31(12):1456-1467. PubMed ID: 35960182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 10 Years of belimumab experience: What have we learnt?
    Levy RA; Gonzalez-Rivera T; Khamashta M; Fox NL; Jones-Leone A; Rubin B; Burriss SW; Gairy K; Maurik AV; Roth DA
    Lupus; 2021 Oct; 30(11):1705-1721. PubMed ID: 34238087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
    Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D
    Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
    Yu X; Chen N; Xue J; Mok CC; Bae SC; Peng X; Chen W; Ren H; Li X; Noppakun K; Gilbride JA; Green Y; Ji B; Liu C; Madan A; Okily M; Tang CH; Roth DA
    Am J Kidney Dis; 2023 Mar; 81(3):294-306.e1. PubMed ID: 36058429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus.
    Oon S; Huq M; Godfrey T; Nikpour M
    Semin Arthritis Rheum; 2018 Oct; 48(2):221-239. PubMed ID: 29426575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.